Table 1.
Patient Characteristics Stratified by Cohort Based on Daptomycin Minimum Inhibitory Concentration
| Characteristic | Enterococcus faecium MIC ≤ 2 µg/mL (n = 31) | Enterococcus faecium MIC 3–4 µg/mL (n = 31) | P Valuea |
|---|---|---|---|
| Demographics | |||
| Age ≥60 y | 18 (58.1) | 21 (67.7) | .43 |
| Male gender | 17 (54.8) | 16 (51.6) | .79 |
| Intensive care unit stay | 11 (35.5) | 14 (45.2) | .44 |
| Immunity and organ function | |||
| Immunosuppressive medication use | 10 (32.3) | 10 (32.3) | 1.00 |
| Any steroid use | 3 (9.7) | 6 (19.4) | .47 |
| Any transplant | 9 (29.0) | 8 (25.8) | .78 |
| Neutropenia | 13 (41.9) | 13 (41.9) | 1.00 |
| Recent chemotherapy | 11 (35.5) | 10 (32.3) | .79 |
| Acute kidney injury | 9 (29.0) | 13 (41.9) | .29 |
| Hemodialysis | 7 (22.6) | 13 (41.9) | .10 |
| Immunosuppressionb | 22 (71.0) | 26 (83.9) | .36 |
| Baseline comorbidities | |||
| Charlson score ≥4 | 12 (38.7) | 15 (48.4) | .44 |
| Any malignancy | 18 (58.1) | 19 (61.3) | .80 |
| Diabetes | 8 (25.8) | 11 (35.5) | .41 |
| Congestive heart failure | 8 (25.8) | 7 (22.6) | .77 |
| Coronary artery disease | 3 (9.7) | 8 (25.8) | .18 |
| Peripheral vascular disease | 1 (3.2) | 1 (3.2) | 1.00 |
| Cerebrovascular disease | 3 (9.7) | 4 (12.9) | 1.00 |
| Dementia | 1 (3.2) | 3 (9.7) | .61 |
| Chronic pulmonary disease | 4 (12.9) | 5 (16.1) | 1.00 |
| Connective tissue disease | 1 (3.2) | 1 (3.2) | 1.00 |
| Ulcer disease | 1 (3.2) | 2 (6.5) | 1.00 |
| Liver disease | 4 (12.9) | 5 (16.1) | 1.00 |
| Hemiplegia | 1 (3.2) | 0 (0.0) | 1.00 |
| Chronic kidney disease | 6 (19.4) | 12 (38.7) | .09 |
| Diabetes with end-organ damage | 2 (6.5) | 7 (22.6) | .15 |
| Metastatic solid tumor | 3 (9.7) | 1 (3.2) | .61 |
| Organism sensitivities and antibiotic history | |||
| Ampicillin resistance | 31 (100.0) | 31 (100.0) | N/A |
| Linezolid resistance | 1 (3.2) | 0 (0.0) | 1.00 |
| Vancomycin resistance | 29 (93.5) | 29 (93.5) | 1.00 |
| Aminoglycoside resistance | 7 (22.6) | 6 (19.4) | .76 |
| Prior daptomycin | 4 (12.9) | 6 (19.4) | .73 |
| Prior ampicillin | 2 (6.5) | 5 (16.1) | .42 |
| Prior vancomycin | 22 (71.0) | 23 (74.2) | .78 |
| Prior aminoglycoside | 1 (3.2) | 4 (12.9) | .35 |
| Initial daptomycin dose ≥8 mg/kg | 18 (58.1) | 17 (54.8) | .80 |
| Infectious sources | |||
| Endocarditis | 0 (0.0) | 1 (3.2) | 1.00 |
| Catheter as potential sourcec | 13 (41.9) | 18 (58.1) | .20 |
| Abdomen as possible sourcec | 12 (38.7) | 9 (29.0) | .42 |
Data are presented as number (%) unless otherwise specified.
Abbreviations: MIC, minimum inhibitory concentration; N/A, not applicable.
a P values based on χ2 or Fisher exact test where appropriate.
b Immunosuppression refers to composite of transplant, neutropenia, immunosuppressive medication use, any steroids, malignancy, and human immunodeficiency virus.
c When the source of infection was documented as deriving from a catheter or the abdomen by the primary treating physician.